StockData
Invivyd, Inc. logo

Invivyd, Inc. (IVVD) stock

IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3048% below fair value
$0.51−0.03 (-4.67%)

Close on Nov 17, 2026Market cap $151.09MP/E –Yield –

Invivyd operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Invivyd's operating cash flow for the twelve months ending Jun 30, 2026 was -$108.42M. For fiscal 2025 it was -$58.14M. The highest annual figure on record is -$58.14M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$58.14M–
FY2024Dec 31, 2024-$170.49M–
FY2023Dec 31, 2023-$173.16M–
FY2022Dec 31, 2022-$219.99M–
FY2021Dec 31, 2021-$184.74M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$43.01M–
Q1 FY2026Mar 31, 2026-$41.71M–
Q4 FY2025Dec 31, 2025-$15.46M–
Q3 FY2025Sep 30, 2025-$8.25M–
Q2 FY2025Jun 30, 2025-$13.30M–
Q1 FY2025Mar 31, 2025-$21.13M–
Q4 FY2024Dec 31, 2024-$37.61M–
Q3 FY2024Sep 30, 2024-$41.07M–
Q2 FY2024Jun 30, 2024-$41.60M–
Q1 FY2024Mar 31, 2024-$50.21M–
Q4 FY2023Dec 31, 2023-$59.24M–
Q3 FY2023Sep 30, 2023-$35.35M–
Q2 FY2023Jun 30, 2023-$37.39M–
Q1 FY2023Mar 31, 2023-$41.18M–
Q4 FY2022Dec 31, 2022-$47.40M–
Q3 FY2022Sep 30, 2022-$56.14M–
Q2 FY2022Jun 30, 2022-$57.39M–
Q1 FY2022Mar 31, 2022-$59.05M–
Q4 FY2021Dec 31, 2021-$73.21M–
Q3 FY2021Sep 30, 2021-$54.21M–
Q2 FY2021Jun 30, 2021-$33.57M–
Q1 FY2021Mar 31, 2021-$23.74M–

More Invivyd figures

See a number that looks wrong?